Myriad Genetics, Inc. (Mygn): Análise de Pestle [Jan-2025 Atualizado]

No cenário em rápida evolução do diagnóstico genético, a Myriad Genetics, Inc. (MYGN) está na interseção de inovação científica inovadora e desafios globais complexos. Essa análise abrangente de pestles revela o ambiente externo multifacetado que molda a trajetória estratégica da empresa, explorando como regulamentos políticos, dinâmica econômica, percepções sociais, avanços tecnológicos, estruturas legais e considerações ambientais influenciam profundamente as operações comerciais da Myriad e o potencial futuro. Ao dissecar essas dimensões críticas, iluminamos o intrincado ecossistema que impulsiona e desafia essa empresa pioneira em testes genéticos, oferecendo informações sem precedentes sobre o cenário estratégico da medicina de precisão.

Myriad Genetics, Inc. (Mygn) - Análise de Pestle: Fatores Políticos

A política de saúde dos EUA muda o impacto no reembolso e regulamentação de testes genéticos

A partir de 2024, a Lei de Acesso à Proteção ao Medicare (PAMA) continua a influenciar as taxas de reembolso de testes genéticos. As taxas de reembolso de testes genéticos do Medicare diminuíram aproximadamente 30-40% desde 2018.

Área de Política	Impacto na inúmeria genética	Efeito financeiro estimado
Reembolso do Medicare	Cobertura reduzida para determinados testes genéticos	US $ 12 a 15 milhões de ajuste anual de receita
Apólices de seguro privado	Critérios mais rígidos de cobertura	Redução potencial de 15 a 20% no volume de teste

Supervisão da FDA das tecnologias de diagnóstico genético

A supervisão da FDA sobre as tecnologias de diagnóstico genético se intensificou, com maior escrutínio regulatório sobre medicina de precisão e plataformas de teste genético.

• 510 (k) Processos de liberação para testes genéticos tornaram -se mais rigorosos
• Custos de conformidade para novas tecnologias de testes genéticos estimados em US $ 500.000 a US $ 1,5 milhão por submissão
• Tempo médio de revisão da FDA para tecnologias de diagnóstico genético: 6-9 meses

Legislação genética de privacidade e proteção de pacientes

A Lei de Não -Discriminação de Informações Genéticas (GINA) continua sendo uma estrutura regulatória crítica para empresas de testes genéticos.

Regulamentação de privacidade	Requisitos de conformidade	Penalidades potenciais
Regras de privacidade genética HIPAA	Proteção estrita de dados do paciente	Até US $ 1,5 milhão anualmente por violações
Leis de privacidade genética em nível estadual	Requisitos adicionais de relatórios e consentimento	Penalidades variáveis ​​por estado

Políticas comerciais internacionais que afetam a tecnologia médica

As políticas comerciais internacionais afetam significativamente as estratégias globais de pesquisa e comercialização da Genriad Genriad.

• As tensões comerciais dos EUA-China têm investimentos em pesquisa colaborativa restritos
• Regulamentos de controle de exportação limitam a transferência de tecnologia em pesquisa genética
• Restrições estimadas de acesso ao mercado global: 12-18% da potencial receita internacional

Investimento de pesquisa e desenvolvimento na navegação de paisagens regulatórias políticas: US $ 8 a 10 milhões anualmente.

Myriad Genetics, Inc. (Mygn) - Análise de Pestle: Fatores econômicos

Cenário volátil de investimento de biotecnologia

A partir do quarto trimestre 2023, o setor de biotecnologia experimentou uma volatilidade significativa do mercado. O preço das ações da Myriad Genetics flutuou entre US $ 14,23 e US $ 22,67 por ação.

Métrica financeira	2023 valor	Mudança de ano a ano
Capitalização de mercado	US $ 752,6 milhões	-15.3%
Receita	$ aproximadamente US $ 670 milhões	-8.2%
Despesas de P&D	US $ 124,5 milhões	+3.7%

Gastos com saúde e medicina de precisão

O mercado global de medicina de precisão projetou atingir US $ 175,7 bilhões até 2028, com um CAGR de 11,2%.

Segmento de mercado de medicina de precisão	2024 Valor estimado
Mercado de testes genéticos	US $ 31,5 bilhões
Teste genético oncológico	US $ 12,8 bilhões

Impacto de cobertura do seguro

A cobertura de testes genéticos varia entre os provedores de seguros:

• O Medicare cobre aproximadamente 80% dos testes genéticos para avaliações específicas de risco de câncer
• As seguradoras privadas cobrem entre 60-85% dos testes genéticos
• Custo médio para os pacientes: US $ 100 a US $ 2.000 por teste

Cenário competitivo

Concorrente	Quota de mercado	Receita anual
Invitae Corporation	7.5%	US $ 541,2 milhões
Natera, Inc.	6.3%	US $ 672,3 milhões
Miríade genética	5.9%	US $ 670 milhões

Desafio econômico -chave: Manter a lucratividade em um mercado de testes genéticos competitivos e em rápida evolução.

Myriad Genetics, Inc. (Mygn) - Análise de Pestle: Fatores sociais

Crescente conscientização e interesse do consumidor na triagem genética de saúde personalizada

De acordo com um relatório de pesquisa de mercado de 2023, o mercado global de testes genéticos diretos ao consumidor foi avaliado em US $ 3,2 bilhões, com um CAGR projetado de 15,5% de 2024 a 2030.

Segmento de mercado	2023 participação de mercado	Crescimento projetado
Triagem de saúde personalizada	42%	18,3% CAGR
Teste de ancestralidade	33%	12,7% CAGR
Teste genético de bem -estar	25%	16,9% CAGR

Considerações éticas em torno dos testes genéticos e potencial discriminação genética

A Lei de Nome -Discriminação de Informações Genéticas (GINA) protege aproximadamente 313 milhões de americanos da discriminação genética no emprego e no seguro de saúde a partir de 2024.

Tipo de discriminação	Casos relatados em 2023	Proteções legais
Discriminação de emprego	287 casos	Totalmente protegido sob Gina
Discriminação do seguro de saúde	193 casos	Totalmente protegido sob Gina

Muda demográfico crescente demanda por câncer hereditário e avaliações de risco genético

Em 2023, os testes genéticos para o risco de câncer hereditário mostraram crescimento significativo, com Aproximadamente 1,9 milhão de testes genéticos realizados para avaliação de risco de câncer.

Faixa etária	Taxa de teste genético	Foco de triagem de câncer primário
40-55 anos	46%	Câncer de mama e ovário
55-70 anos	38%	Câncer colorretal e de próstata
Menos de 40 anos	16%	Triagem preventiva

As atitudes culturais em relação aos testes genéticos e medicina de precisão variam globalmente

As atitudes globais em relação aos testes genéticos revelam variações regionais significativas nas taxas de aceitação e adoção.

Região	Taxa de aceitação de testes genéticos	Motivação primária
América do Norte	68%	Prevenção de riscos à saúde
Europa	55%	Pesquisa médica
Ásia-Pacífico	42%	Descoberta de ancestralidade
Médio Oriente	35%	Considerações culturais e religiosas

Myriad Genetics, Inc. (Mygn) - Análise de Pestle: Fatores tecnológicos

Avanços contínuos em tecnologias de sequenciamento de próxima geração

A Miríade Genetics investiu US $ 78,3 milhões em P&D para tecnologias de sequenciamento em 2023. As plataformas de sequenciamento de próxima geração da empresa processam 1,2 milhão de testes genéticos anualmente com 99,7% de precisão.

Métrica de tecnologia	2023 desempenho	2024 Projetado
Velocidade de sequenciamento	24 horas por teste	18 horas por teste
Cobertura genômica	22.000 genes	25.000 genes
Capacidade de processamento de dados	500 TB/mês	750 TB/mês

Aprendizado de máquina e integração de IA na análise e interpretação de dados genéticos

Miríade genética implantou US $ 45,2 milhões em infraestrutura de IA, desenvolvendo 17 algoritmos de aprendizado de máquina para previsão de risco genético com 92,4% de precisão preditiva.

Métricas de tecnologia da IA	Desempenho atual
Modelos de aprendizado de máquina	17 modelos ativos
Velocidade de processamento de dados da IA	3,6 milhões de pontos de dados/hora
Precisão computacional	92.4%

Expandindo as capacidades de teste genético para avaliação complexa de risco de doenças

Miríade genética expandiu o portfólio de testes genéticos para 35 painéis de risco de doenças complexas, cobrindo 412 marcadores genéticos com investimento de US $ 62,7 milhões em 2023.

Aumentar o poder computacional, permitindo pesquisas genéticas mais sofisticadas

A empresa atualizou a infraestrutura computacional com investimento de US $ 53,4 milhões, aumentando os recursos de processamento de pesquisa para 2,8 petaflops, permitindo uma análise genética mais complexa.

Recursos computacionais	2023 Capacidade	2024 Capacidade projetada
Poder de processamento	2.8 PETAFLOPS	3.5 PETAFLOPS
Capacidade de armazenamento	4.2 Petabytes	5.7 Petabytes
Pesquisa velocidade de computação	1,2 trilhão de cálculos/segundo	1,7 trilhão de cálculos/segundo

Myriad Genetics, Inc. (Mygn) - Análise de Pestle: Fatores Legais

Conformidade com HIPAA e regulamentos de privacidade de dados genéticos

Métricas de conformidade HIPAA para inúmeras genética:

Aspecto de conformidade	Dados específicos
Taxa anual de conformidade de auditoria HIPAA	98.7%
Incidentes de violação de dados (2023)	0 incidentes relatáveis
Investimento de proteção de dados do paciente	US $ 3,2 milhões anualmente

Proteções de patentes para metodologias de teste genético

Patente portfólio Redução:

Categoria de patentes	Número de patentes ativas	Faixa de expiração da patente
Tecnologias de testes genéticos	37 patentes ativas	2026-2035
Metodologias de diagnóstico	22 patentes ativas	2027-2033

Riscos potenciais de litígios

Estatísticas de litígios:

Categoria de litígio	Número de casos	Total de despesas legais
Acender os processos de precisão de testes genéticos	3 casos ativos	US $ 1,5 milhão em custos legais
Casos resolvidos (2023)	2 casos	US $ 750.000 em assentamentos

Requisitos regulatórios para marketing de teste genético

Métricas de conformidade regulatória:

Órgão regulatório	Status de conformidade	Custo anual de verificação de conformidade
Aprovações de teste genético da FDA	12 testes aprovados	US $ 2,8 milhões
Submissões de validação clínica	8 envios bem -sucedidos	US $ 1,6 milhão em processamento regulatório

Despesas de conformidade regulatória: US $ 4,4 milhões anualmente na manutenção dos padrões regulatórios de testes genéticos.

Myriad Genetics, Inc. (Mygn) - Análise de Pestle: Fatores Ambientais

Práticas laboratoriais sustentáveis ​​e gestão de resíduos em pesquisa genética

A miríade de genética relatou redução de 78,3% na geração de resíduos perigosos em seu relatório de sustentabilidade de 2022. A empresa implementou protocolos abrangentes de segregação de resíduos em 12 instalações de pesquisa.

Categoria de resíduos	Volume anual (kg)	Taxa de reciclagem
Resíduos biológicos	4.562 kg	62.4%
Resíduos químicos	1.876 kg	45.7%
Consumíveis de laboratório plástico	3.245 kg	71.3%

Iniciativas de eficiência energética em pesquisas genômicas e instalações de diagnóstico

A inútil genética investiu US $ 2,3 milhões em atualizações de eficiência energética durante 2022-2023, alcançando uma redução de 24,6% no consumo total de energia.

Tipo de instalação	Consumo de energia (MWH)	Porcentagem de energia renovável
Laboratórios de pesquisa	4.562 mwh	18.7%
Centros de diagnóstico	2.876 mwh	22.3%
Escritórios corporativos	1.245 mwh	15.9%

Impacto ambiental potencial de testes genéticos e materiais de pesquisa

A avaliação da pegada de carbono revelou 12,4 toneladas métricas de emissões de CO2 por instalação de pesquisa anualmente. A empresa implementou programas de compensação de carbono, cobrindo 68% do total de emissões.

Objetivos de sustentabilidade corporativa e compromissos de responsabilidade ambiental

Miríade genética comprometida em alcançar a neutralidade de carbono até 2030, com alvos intermediários, incluindo:

• Redução de 40% no escopo 1 e 2 emissões até 2025
• 75% compras sustentáveis ​​até 2027
• Aquisição de energia 100% renovável para instalações de pesquisa até 2028

Métrica de sustentabilidade	2022 Performance	Alvo de 2030
Redução de emissões de carbono	24.6%	85%
Uso de energia renovável	19.3%	100%
Taxa de reciclagem de resíduos	62.4%	90%

Myriad Genetics, Inc. (MYGN) - PESTLE Analysis: Social factors

You're looking at how public sentiment and societal trends are shaping the environment for Myriad Genetics, Inc. (MYGN) right now, in late 2025. Honestly, the social landscape is a double-edged sword: massive demand for personalized health insights clashing with deep-seated privacy fears. Here's how those forces are playing out for the business.

Growing consumer demand for personalized medicine and proactive genetic health risk screening is expanding the market

The push for personalized medicine is real, and it's driving serious market expansion. Globally, the Personalized Medicine market was valued at an estimated $531.7 billion in 2024 and is on track to hit $869.9 billion by 2030, growing at a compound annual rate of 8.5%. This isn't just academic; it translates directly to volume for Myriad Genetics, Inc. The company projects its hereditary cancer testing revenue alone will be about $370 million for fiscal year 2025, which is roughly 45% of their total expected revenue of $818 million to $828 million. Oncology remains the biggest application area, holding an estimated 40.2% share of the personalized medicine market in 2024. People want to know their risks before something happens. That's the tailwind.

Focus on the Cancer Care Continuum (CCC) aligns with public health trends for early detection and recurrence monitoring

Myriad Genetics, Inc. is smartly pivoting its strategy to cover the entire Cancer Care Continuum (CCC), which perfectly matches public health's focus on catching cancer early and monitoring survivors. This means moving beyond just initial hereditary risk assessment into areas like therapy selection and recurrence monitoring. The company is leaning heavily on this, with its upcoming Precise MRD (Minimal Residual Disease) test-a whole-genome sequencing assay-slated for a commercial launch in 2026. This shift acknowledges that patients and oncologists need actionable data at every stage of the cancer journey, not just at the beginning. It's about making genetic insights a continuous part of care, which is exactly where the industry is heading.

Ethical and social concerns regarding genetic data privacy and use could reduce patient willingness to test

Here's where things get tricky. Despite the demand, trust is fragile. A significant portion of consumers-about 50%-report being extremely or very concerned about for-profit DNA testing companies sharing their genetic information without explicit consent. This concern is amplified by new regulatory realities in 2025. For instance, the Department of Justice's "Bulk Data Rule," effective April 8, 2025, restricts transfers of human 'omic data, even if it's anonymized, if it risks access by certain entities. Furthermore, states are tightening rules; Montana's SB 163 amends its Genetic Information Privacy Act, effective October 1, 2025, to address deidentified data use. If patients fear their deeply personal data is insecure or will be used against them by insurers or employers-where 87% of respondents feel it should be illegal for that to happen-they will simply opt out of testing.

The company maintains one of the largest teams of board-certified genetic counselors to support patient-physician communication

To counter the complexity and privacy fears, you need human expertise to bridge the gap between a lab report and a clinical decision. Myriad Genetics, Inc. has recognized this by building out a substantial support structure. They currently have more than 50 board-certified genetic counselors available to speak with patients during business hours. This team handles pre- and post-test support in over 200+ languages, 5 days a week, often with average call times under 12 minutes and wait times under three minutes. This service is designed to complement, not compete with, local clinical resources, ensuring that when a complex result comes back, there's an expert available to explain the implications clearly. It's a tangible action addressing the social need for informed consent and interpretation.

Here's a quick snapshot of the social and operational context for Myriad Genetics, Inc. as of late 2025:

Metric	Value/Context (2025 Fiscal Year Data)
Projected FY2025 Total Revenue Range	$818 million to $828 million
Hereditary Cancer Testing Revenue (Est. FY2025)	Approx. $370 million (approx. 45% of total sales)
Board-Certified Genetic Counselors on Staff	More than 50
Average Patient Wait Time for GC Support	Less than three minutes
Consumer Concern: Data Sharing by For-Profit Companies	50% extremely or very concerned
Key Regulatory Event (Federal)	DOJ Bulk Data Rule effective April 8, 2025

What this estimate hides is the impact of payer mix and specific coverage decisions, like UnitedHealthcare's policy, which has pressured average selling prices (ASPs) throughout the year. Finance: draft 13-week cash view by Friday.

Myriad Genetics, Inc. (MYGN) - PESTLE Analysis: Technological factors

When we look at Myriad Genetics, Inc. (MYGN) from a technology lens, it's clear they are heavily investing in upgrading their core offerings and pushing into the next generation of diagnostics. You need to understand these pipeline moves because they directly impact future revenue streams and competitive positioning against rivals in the genomic space. The focus is clearly on expanding actionable data points and leveraging artificial intelligence to enhance prognostic power.

Launching an expanded MyRisk Hereditary Cancer Test panel in late 2025 will incorporate more clinically actionable genes

Myriad Genetics just wrapped up a significant upgrade to its flagship MyRisk Hereditary Cancer Test in November 2025. This isn't just a minor tweak; they added 15 new clinically actionable genes to the panel. This brings the total to 63 carefully selected genes covering more than 11 cancer types. The key here is clinical actionability-these additions are based on recommendations from bodies like the NCCN and ASCO, meaning they directly influence treatment or surveillance plans. For you, this means the test is now more comprehensive, which should help drive volume, especially since 1 in 4 women without cancer may qualify for germline testing.

Integrating AI-powered technology (PATHOMIQ) into the Prolaris prostate cancer test will enhance prognostic prediction in 2026

The move to integrate Artificial Intelligence is a big one for the Prolaris Prostate Cancer Prognostic Test. Myriad is bringing in PATHOMIQ's AI platform, PATHOMIQ_PRAD, which analyzes digitized H&E (Hematoxylin and Eosin) pathology images. The goal is to launch this AI-enhanced version in early 2026. What this upgrade does is layer AI-driven morphologic insights on top of the existing genomic data from Prolaris, aiming for better prediction of outcomes like biochemical recurrence and metastasis. Honestly, the promise is a rapid turnaround time-results in 1 to 2 days-which beats traditional molecular testing timelines of 5 to 7 days.

The Precise Molecular Residual Disease (MRD) test, a key pipeline asset, is slated for early access launch in the first half of 2026

The Precise Molecular Residual Disease (MRD) test is where Myriad is making a major play in the liquid biopsy space. This test is tumor-informed and uses Whole Genome Sequencing (WGS) to monitor hundreds to thousands of tumor-specific variants, offering exceptional sensitivity. While it is currently available for research studies, the commercial launch is targeted for 2026. Interim data from the MONSTAR-SCREEN-3 study showed impressive results, achieving 100% baseline detection across tumor types. This ultra-sensitivity is a critical differentiator, potentially allowing for the detection of recurrence at levels missed by first-generation tests, where 60% of positive samples were in the ultra-sensitive range.

Here's the quick math on these key technology milestones:

Product/Technology	Key Feature/Update	Targeted Timeline
MyRisk Hereditary Cancer Test	Expanded to 63 actionable genes	Late 2025 (Completed)
Prolaris Test + PATHOMIQ AI	Integration of AI for prognostic enhancement	Early 2026
Precise MRD Test	Commercial Launch (WGS-based, ultra-sensitive)	2026

What this estimate hides is the execution risk; getting these complex tests through validation and into broad clinical adoption takes time and capital.

Rapid advancements in Next-Generation Sequencing (NGS) lower testing costs, intensifying competition from rivals

The entire molecular diagnostics field is being reshaped by the falling cost curve of Next-Generation Sequencing (NGS) technology. Sophisticated NGS platforms are gaining FDA clearance in 2025, focusing on high-throughput, pan-cancer profiling. This technological democratization means rivals-including players like Guardant Health and Invitae-can enter the market with competitive panel tests at lower price points than older methods. For Myriad, which is already seeing a 3% decline in Q1 2025 revenue year-over-year, this competitive pressure is real, especially as reimbursement methodologies like PAMA continue to challenge payment levels. You must watch how Myriad leverages its proprietary data and clinical interpretation expertise to maintain a premium over lower-cost NGS competitors.

Finance: draft a sensitivity analysis on Prolaris revenue assuming a 15% price erosion due to new AI/NGS competitors by Q4 2026, due next Wednesday.

Myriad Genetics, Inc. (MYGN) - PESTLE Analysis: Legal factors

You're navigating a legal landscape that is both shaped by a decade-old Supreme Court decision and actively being reformed by Congress right now, which directly impacts your ability to protect your diagnostic innovations.

The landmark AMP v. Myriad Supreme Court case from 2013 remains the bedrock of current patent law for diagnostics: it invalidated patents on naturally occurring DNA, meaning you can't patent the isolated BRCA1 or BRCA2 genes themselves. This ruling immediately lowered the barrier to entry, leading to increased competition in genetic testing, which you see reflected in the market today. For instance, while your Hereditary Cancer testing volume grew 11% year-over-year in Q3 2025, that growth happens in a market where competitors can offer similar tests without the patent hurdles Myriad once faced. Honestly, the decision was a watershed moment that opened the door for broader access, but it also means your R&D spend must now be protected by method or application patents, not the underlying gene sequence. That's the key difference.

Ongoing Legislative Efforts to Restore Patent Eligibility

Congress is actively trying to clean up the uncertainty created by the Supreme Court's judicial exceptions, which have affected more than just genes. The Patent Eligibility Restoration Act of 2025 (PERA), introduced in the Senate and House on May 1, 2025, is the primary focus, having seen a hearing in the Senate Judiciary Subcommittee on Intellectual Property on October 8, 2025. This bipartisan bill aims to clarify what is patent-eligible under 35 U.S.C. § 101. What this estimate hides is that PERA is a measured approach; it would codify the Myriad holding that unmodified human genes are not patentable, but it seeks to restore eligibility for diagnostic methods that were previously struck down under the Mayo framework. If passed, this could give Myriad stronger protection for novel testing methodologies.

Here's a quick look at how the proposed PERA 2025 legislation handles the core issues:

• Restores eligibility for many diagnostic inventions.
• Maintains that unmodified human genes are ineligible.
• Clarifies that synthetic or modified genes may qualify.
• Aims to reverse uncertainty from Alice and Mayo rulings.

Genetic Information Nondiscrimination Act (GINA) Compliance

The Genetic Information Nondiscrimination Act (GINA), enacted in 2008, continues to protect individuals from discrimination in health insurance and employment based on their genetic test results. For Myriad, this means strict protocols around how genetic data is handled, stored, and reported to avoid any implication of sharing results that could lead to adverse employment or insurance decisions. While I don't have a specific line item for GINA compliance costs in the Q3 2025 filing, you must assume these internal controls and training are baked into your operating expenses, which totaled $167.1 million in the third quarter of 2025.

Global Data Privacy and International Operations

Any international expansion or distribution, like the one where you divested the international EndoPredict business in August 2024, immediately subjects you to a patchwork of global regulations. As noted in your February 28, 2025 10-K filing, compliance with laws like the EU's General Data Protection Regulation (GDPR) is a key risk. This isn't just about fines; it's about the logistical complexity of transferring patient samples and data across borders while adhering to conflicting national requirements. If you plan to re-enter or expand in Europe, the cost of maintaining GDPR-compliant data infrastructure is a non-trivial fixed cost that must be modeled into your international revenue projections.

The current patent landscape for diagnostics is a balancing act between past rulings and future legislation:

Legal Element	Status Post-2013 (Myriad Ruling)	Proposed Status (PERA 2025 - S.1546)
Isolated, Naturally Occurring DNA	Not Patent Eligible (Product of Nature)	Remains Not Patent Eligible (Codified)
Synthetic DNA (cDNA)	Patent Eligible (Man-made)	Likely Remains Patent Eligible
Diagnostic Methods/Tests	Highly Uncertain (Subject to Mayo Test)	Restored to Patent Eligibility if not abstract/law of nature
Incentive for Diagnostic Investment	Reduced/Uncertainty High	Aimed at Increasing Confidence/Investment

If onboarding international data processing agreements takes longer than expected, your ability to launch new global tests definitely stalls.

Finance: draft the projected compliance overhead for a hypothetical EU market re-entry based on GDPR requirements by Friday.

Myriad Genetics, Inc. (MYGN) - PESTLE Analysis: Environmental factors

You're looking at the environmental side of Myriad Genetics' operations, and honestly, it's a classic lab-based challenge: balancing high-throughput testing with a low footprint. The pressure here isn't just about public perception; it's about managing the sheer volume of consumables required for genetic sequencing and diagnostics.

The company is actively tackling this through modernization. The Labs of the Future initiative is key; it's designed to overhaul facilities to be more efficient, which naturally means a smaller environmental impact. This isn't just a feel-good project; the expectation is that these modernized facilities will yield reduced operating costs, which is a tangible financial benefit alongside the green one.

Waste Management and Resource Use

The most concrete data point we have for recent efforts comes from their corporate responsibility reporting. For the reporting period covering January 1, 2023, through September 30, 2024, Myriad Genetics reported recycling 46.9 tons of plastic waste specifically from their Salt Lake City laboratories. That's a solid chunk of material diverted from landfills, which is critical when you consider the nature of lab consumables.

Still, the core challenge remains the management of specialized waste streams. High-volume testing facilities generate significant biohazardous lab waste that requires specialized, energy-intensive disposal methods. Furthermore, the company faces ongoing scrutiny regarding the carbon footprint tied to its supply chain logistics-getting those delicate biological samples to and from the labs via commercial courier services is a constant consideration for any firm in this space.

Here's a quick look at what we know about their recent environmental performance metrics:

Environmental Metric	Value/Period	Source/Context
Plastic Recycled (SLC Labs)	46.9 tons	Reporting Period: Jan 1, 2023 - Sep 30, 2024
Plastic Recycled (Cumulative since 2019)	Approx. 102 tons	As of the 2022 ESG Report
Solar Energy System Capacity	495-kilowatt	At the Myriad Support Center
Scope 1 & 2 Emissions Data	Disclosed	In the 2023-2024 Quality, Innovation, and Corporate Responsibility Report

Energy and Infrastructure Modernization

Energy consumption is a major factor for any large-scale molecular diagnostic operation. To be fair, the company has already made infrastructure moves, like installing a 495-kilowatt photovoltaic solar energy system at its Support Center to offset electricity use. The newer facilities, including those in South San Francisco, are being built with energy and water efficiency in mind.

The success of the Labs of the Future initiative is what investors are watching closely here, as it promises to streamline workflows and directly lower operating costs, which often correlates with reduced energy intensity per test. The pressure to reduce overall energy consumption in these high-volume testing facilities is real, and capital expenditure decisions in 2025 will reflect this priority.

Key environmental focus areas moving into 2025 include:

• Finalizing 'Labs of the Future' rollout.
• Managing biohazardous waste disposal costs.
• Reducing courier-related carbon emissions.
• Improving environmental footprint assessment.

If onboarding the new lab tech takes longer than expected, those energy efficiency gains will be delayed.

Finance: draft 13-week cash view by Friday